AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2016 Issue 4; ICD-10-CM NEW/REVISED CODES
Abnormal Prostate Specific Antigen (PSA) Levels
Code R97.2, Elevated prostate specific antigen [PSA], has been expanded to create separate codes to distinguish elevated PSA from a rise in PSA following treatment. Codes R97.20, Elevated prostate specific antigen [PSA]), and R97.21, Rising PSA following treatment for malignant neoplasm of prostate, are included in category R97, Abnormal tumor markers. The first step in treatment for a patient with an elevated PSA level is to attempt to suppress that level with hormone therapy or a similar therapy, such as removal of the testicles. When the PSA drops due to hormone therapy, the tumor is considered...
Subscribe or sign in to view the full article.
Article Overview
This article explains a coding update in ICD-10-CM category R97 for abnormal tumor markers, with a focus on prostate-specific antigen (PSA) levels. It is intended for coders, billers, and clinical documentation teams who need to understand how the topic is being separated for tracking purposes and why the change matters for reporting patients with elevated or changing PSA values after treatment.
Why This Topic Matters
Clear PSA-related documentation and coding support more accurate tracking of patients with abnormal tumor markers over time, especially in the context of follow-up after therapy for prostate malignancy.
What You Will Learn
- How the article frames the ICD-10-CM update related to PSA findings
- Why PSA-related coding changes matter for post-treatment patient tracking
- How the article situates PSA-related codes within the broader abnormal tumor marker category
- What general clinical context is discussed around treatment response and follow-up
Who Should Read This
- Medical coders
- Coding auditors
- Clinical documentation specialists
- Revenue cycle staff
- Physician practices
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com